Sino Biopharmaceut (SBMFF) Rating Lowered to Hold at Zacks Investment Research

Sino Biopharmaceut (OTCMKTS:SBMFF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, January 10th.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Sino Biopharmaceut (OTCMKTS SBMFF) opened at $1.80 on Wednesday. Sino Biopharmaceut has a 1-year low of $0.72 and a 1-year high of $1.98.

ILLEGAL ACTIVITY NOTICE: “Sino Biopharmaceut (SBMFF) Rating Lowered to Hold at Zacks Investment Research” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at

About Sino Biopharmaceut

Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.

Get a free copy of the Zacks research report on Sino Biopharmaceut (SBMFF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply